Publicacións (147) Publicacións nas que participase algún/ha investigador/a

2021

  1. 60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)

    Annals of Oncology, Vol. 32, pp. S46

  2. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. A roadmap for medical treatment of metastatic CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 365-379

  4. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

    Nature Communications, Vol. 12, Núm. 1

  5. Acquisition of new migratory properties by highly differentiated cd4+cd28null t lymphocytes in rheumatoid arthritis disease

    Journal of Personalized Medicine, Vol. 11, Núm. 7

  6. Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study

    Advances in Therapy, Vol. 38, Núm. 1, pp. 290-303

  7. Advanced multi-dimensional cellular models as emerging reality to reproduce In Vitro the human body complexity

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-28

  8. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study

    Translational Lung Cancer Research, Vol. 10, Núm. 10, pp. 3902-3911

  9. Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol

    PLoS ONE, Vol. 15, Núm. 12 December

  10. Assessment of saliva and oral candidiasis levels 12, 24 and 36 months after radiotherapy in patients with head and neck cancer

    Journal of Stomatology, Oral and Maxillofacial Surgery, Vol. 122, Núm. 6, pp. 566-572

  11. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

    JTO Clinical and Research Reports, Vol. 2, Núm. 3

  12. Biodistribution of 68/67Ga-radiolabeled sphingolipid nanoemulsions by pet and spect imaging

    International Journal of Nanomedicine, Vol. 16, pp. 5923-5935

  13. Blood-based protein biomarkers in bladder urothelial tumors

    Journal of Proteomics, Vol. 247

  14. Breast cancer

    Medicine (Spain), Vol. 13, Núm. 27, pp. 1506-1517

  15. Breast cancer patient experiences through a journey map: A qualitative study

    PLoS ONE, Vol. 16, Núm. 9 September

  16. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 12, pp. 2091-2108

  17. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  18. Case-control analysis of the impact of anemia on quality of life in patients with cancer: A Qca study analysis

    Cancers, Vol. 13, Núm. 11

  19. Chapter 16: Cyclodextrin-based Drug Delivery Systems Manufactured by Emergent Technologies: 3D-printing, Electrospinning, Microneedles, Microfluidics and MOFs

    RSC Soft Matter (Royal Society of Chemistry), pp. 405-424

  20. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871